Search research articles
Contact Us
Filters
Showing results (101-110 of 138) with videos related to
Page
of 14
Sort By:
International Journal of Cancer
|
December 7, 2017
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Stuart J Gallagher, Dilini Gunatilake, Kimberley A Beaumont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer
Lyndee L Scurr, Alexander D Guminski, Yoke-Eng Chiew, et al.
NPJ Precision Oncology
|
May 30, 2026
Distinctive features of the tumor and immune microenvironment in glioblastoma
Elena Shklovskaya, Bernadette Pedersen, Su Yin Lim, et al.
Nature Communications
|
March 19, 2023
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Su Yin Lim, Elena Shklovskaya, Jenny H Lee, et al.
Cells
|
July 11, 2025
COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
Ada Ndoja, Christopher M Rose, Eva Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2018
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y Lim, Jenny H Lee, Tuba N Gide, et al.
The Journal of Clinical Investigation
|
May 29, 2014
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Jamie N Anastas, Rima M Kulikauskas, Tigist Tamir, et al.
Cancers
|
November 18, 2020
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Elena Shklovskaya, Jenny H Lee, Su Yin Lim, et al.
Oncotarget
|
November 20, 2020
Detection of <i>BRAF</i> splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
Michael E Clark, Helen Rizos, Michelle R Pereira, et al.
Nature Communications
|
December 3, 2014
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V Long, Carina Fung, Alexander M Menzies, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 138) with videos related to
Sort By:
Page
of 14
International Journal of Cancer
|
December 7, 2017
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Stuart J Gallagher, Dilini Gunatilake, Kimberley A Beaumont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer
Lyndee L Scurr, Alexander D Guminski, Yoke-Eng Chiew, et al.
NPJ Precision Oncology
|
May 30, 2026
Distinctive features of the tumor and immune microenvironment in glioblastoma
Elena Shklovskaya, Bernadette Pedersen, Su Yin Lim, et al.
Nature Communications
|
March 19, 2023
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Su Yin Lim, Elena Shklovskaya, Jenny H Lee, et al.
Cells
|
July 11, 2025
COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
Ada Ndoja, Christopher M Rose, Eva Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2018
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y Lim, Jenny H Lee, Tuba N Gide, et al.
The Journal of Clinical Investigation
|
May 29, 2014
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Jamie N Anastas, Rima M Kulikauskas, Tigist Tamir, et al.
Cancers
|
November 18, 2020
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Elena Shklovskaya, Jenny H Lee, Su Yin Lim, et al.
Oncotarget
|
November 20, 2020
Detection of <i>BRAF</i> splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
Michael E Clark, Helen Rizos, Michelle R Pereira, et al.
Nature Communications
|
December 3, 2014
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V Long, Carina Fung, Alexander M Menzies, et al.
Page
of 14